

# SUPPORTING INFORMATION

## **Cannabizetol, a Novel Cannabinoid: Chemical Synthesis, Anti-inflammatory Activity and Extraction from *Cannabis sativa* L.**

Luca Pozzi,<sup>a</sup> Andrea Gotti,<sup>b</sup> Marco Fumagalli,<sup>c</sup> Andrea Citarella,<sup>a</sup> Valerio Fasano,<sup>a</sup> Giuseppe Paladino,<sup>d</sup> Umberto Ciriello,<sup>d</sup> Salvatore Princiotto,<sup>b</sup> Francesca Annunziata,<sup>b</sup> Giulia Martinelli,<sup>c</sup> Enrico Sangiovanni,<sup>c</sup> Andrea Pinto,<sup>b</sup> Mario Dell'Agli,<sup>c</sup> Daniele Passarella.\*<sup>a</sup>

<sup>a</sup> Department of Chemistry, Università degli Studi di Milano, 20133 Milan, Italy.

<sup>b</sup> Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy.

<sup>c</sup> Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, 20133 Milan, Italy.

<sup>d</sup> LINNEA SA, 6595 Riazzino (TI), Switzerland.

Corresponding: [daniele.passarella@unimi.it](mailto:daniele.passarella@unimi.it)


Contents	Pages
<b>1. Continuous reaction conditions screening for cannabizetol</b>	S1
<b>2. Cytotoxicity tests</b>	S2
<b>3. Gene expression tests</b>	S3 – S4
<b>4. <sup>1</sup>H and APT NMR spectra of cannabitwinol (6)</b>	S5 – S6
<b>5. <sup>1</sup>H, APT and 2D NMR spectra of cannabizetol (7)</b>	S7 – S12
<b>6. <sup>1</sup>H and APT NMR spectra of intermediates 8, 9, 10, 11, 12</b>	S13 – S22
<b>7. HPLC traces of cannabitwinol (6) and cannabizetol (7)</b>	S23 – S26

## 1. Continuous reaction conditions screening for cannabizetol

**Supplementary Table S1:** Reaction conditions screening for continuous synthesis of cannabizetol (7).


Entry	T (°C)	P (bar)	Res. time (min)	Molar ratio CBG:CH <sub>2</sub> O	Catalyst Molar Ratio CBG:Cat.	Yield (%)
1	100	5	90	1:3	-	no product
2	120	5	90	1:3	-	traces
3	140	7	90	1:3	-	6
4	140	7	180	1:3	-	6
5	140	7	90	1:100	-	traces
6	140	7	90	1:0.5	-	12
7	140	7	90	1:0.5	<i>p</i> TSA (1:0.1)	degradation
8	140	7	90	1:0.5	TEA (1:5)	20
9	140	7	90	1:0.5	TEA (1:0.5)	12
10	140	7	90	1:0.5	TEA (1:1)	12
11	140	7	90	1:0.5	TEA (1:10)	12
12	140	7	60	1:0.5	TEA (1:5)	9
13	140	7	30	1:0.5	TEA (1:5)	3

## 2. Cytotoxicity tests




**Supplementary Figure S1.** Cytotoxicity assay (MTT test) of cannabinoids **6** (A) and **7** (B), in HaCaT cells treated with concentrations ranging from 0.5 to 20  $\mu\text{M}$ . Data are reported as percentage in comparison to the control (mean  $\pm$  SEM), which was arbitrarily assigned 100% value.

### 3. Gene expression tests




**Supplementary Figure S2.** Effect of TNF $\alpha$  (10 ng/mL) on gene expression of 84 genes related to the inflammatory process. The Volcano Plot identifies significant gene expression changes by plotting the  $\log_2$  of the fold changes in gene expression on the x-axis versus their statistical significance on the y-axis (p-value threshold: 0.05). The center vertical line indicates unchanged gene expression, while the two outer vertical lines indicate the selected fold regulation threshold (fold regulation threshold: 2).




**Supplementary Figure S3.** Effect of cannabigerol (A) and compound **7** (B) at concentration of 5  $\mu$ M on TNF $\alpha$ -induced gene expression of 84 genes related to the inflammatory process. The Volcano Plot identifies significant gene expression changes by plotting the log<sub>2</sub> of the fold changes in gene expression on the x-axis versus their statistical significance on the y-axis (p-value threshold: 0.05). The center vertical line indicates unchanged gene expression, while the two outer vertical lines indicate the selected fold regulation threshold (fold regulation threshold: 2).

#### 4. <sup>1</sup>H and APT NMR spectra of cannabitwinol (6)




Supplementary Figure S4. <sup>1</sup>H-NMR spectra (400 MHz, CD<sub>3</sub>OD) of 6.




Supplementary Figure S5. APT NMR spectra (101 MHz, CD<sub>3</sub>OD) of 6.


5.  $^1\text{H}$ , APT and 2D NMR spectra of cannabizetol (7)




**Supplementary Figure S6.** Comparison of the  $^1\text{H}$  NMR (400 MHz) spectra of CBG (on top, in green) and cannabizetol (on bottom, in red) in  $\text{MeOH-}d_4$  at 25  $^\circ\text{C}$ .




Supplementary Figure S7. <sup>1</sup>H-NMR spectra (400 MHz, MeOH-*d*<sub>4</sub>) of 7.




Supplementary Figure S8. APT NMR spectra (101 MHz, MeOH-*d*<sub>4</sub>) of 7.



**Supplementary Figure S9.** 2D NMR COSY spectra of compound **7** in MeOH-*d*<sub>4</sub>.




**Supplementary Figure S10.** 2D NMR HSQC spectra of compound **7** in MeOH- $d_4$ .




Supplementary Figure S11. 2D NMR HMBC spectra of compound 7 in MeOH- $d_4$ .


## 6. $^1\text{H}$ and APT NMR spectra of intermediates 8, 9, 10, 11, 12




Supplementary Figure 12.  $^1\text{H}$ -NMR spectra (400 MHz,  $\text{CDCl}_3$ ) of 8.




Supplementary Figure S13. APT NMR spectra (101 MHz, CDCl<sub>3</sub>) of **8**.




Supplementary Figure S14. <sup>1</sup>H-NMR spectra (400 MHz, CDCl<sub>3</sub>) of 9.




Supplementary Figure S15. APT NMR spectra (101 MHz, CDCl<sub>3</sub>) of 9.




Supplementary Figure S16. <sup>1</sup>H-NMR spectra (400 MHz, CDCl<sub>3</sub>) of 10.




Supplementary Figure S17. ZGDC NMR spectra (101 MHz, CDCl<sub>3</sub>) of 10.




Supplementary Figure S18. <sup>1</sup>H-NMR spectra (400 MHz, CDCl<sub>3</sub>) of 11.



Supplementary Figure S19. APT NMR spectra (101 MHz, MeOH-*d*<sub>4</sub>) of 11.




**Supplementary Figure S20.** <sup>1</sup>H-NMR spectra (400 MHz, CDCl<sub>3</sub>) of **12**.




Supplementary Figure S21. APT NMR spectra (101 MHz, CDCl<sub>3</sub>) of 12.


## 7. HPLC traces of cannabitwinol (6) and cannabizetol (7)




**Supplementary Figure S22.** HPLC chromatogram of compound **6**: Agilent 1100 Series System RP column ZORBAX SB C8 (3.5  $\mu\text{m}$  x 4.6 x 150 mm), flow rate of 1.2 mL/min, UV spectra recorded at 254 nm and 220 nm with DAD detection, mobile phase H<sub>2</sub>O/MeOH. Method: gradient for 30 min from 80% to 100% MeOH.



**Supplementary Figure S23.** HPLC chromatogram of compound **7**: Agilent 1100 Series System RP column ZORBAX SB C8 (3.5  $\mu$  m x 4.6 x 150 mm), flow rate of 1.2 mL/min, UV spectra recorded at 254 nm and 220 nm with DAD detection, mobile phase H<sub>2</sub>O/MeOH. Method: gradient for 30 min from 80% to 100% MeOH.



**Supplementary Figure S24.** HPLC chromatogram of 1:1 mixture of compound **6** and **7**: Agilent 1100 Series System RP column ZORBAX SB C8 (3.5  $\mu$  m x 4.6 x 150 mm), flow rate of 1.2 mL/min, UV spectra recorded at 254 nm and 220 nm with DAD detection, mobile phase H<sub>2</sub>O/MeOH. Method: gradient for 30 min from 80% to 100% MeOH.



**Supplementary Figure S25.** Superimposition (A) and close up view at 24 min (B) of HPLC chromatograms of crude extract from *Cannabis sativa* raw material (in red), pure cannabizetol (7) obtained from extraction process (in blue) and pure cannabizetol (7) obtained from synthesis (in black). HPLC condition according to Ph. Eur. monograph 07/2024:3151 (Cannabidiol).